{"id":54897,"date":"2026-01-20T20:46:26","date_gmt":"2026-01-20T12:46:26","guid":{"rendered":"https:\/\/flcube.com\/?p=54897"},"modified":"2026-01-20T20:46:28","modified_gmt":"2026-01-20T12:46:28","slug":"ocumensions-ot-703-dme-implant-enrolls-195-patients-in-china-real-world-study","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54897","title":{"rendered":"Ocumension\u2019s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study"},"content":{"rendered":"\n<p><strong>Ocumension Therapeutics<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1477:HKG\">HKG: 1477<\/a>) announced completion of enrollment for a <strong>real\u2011world study<\/strong> of <strong>OT-703 (fluocinonide intravitreal implant)<\/strong> in <strong>Bo\u2019ao Lecheng International Medical Tourism Pilot Zone<\/strong>, enrolling <strong>195 patients<\/strong> with <strong>diabetic macular edema (DME)<\/strong> as the company advances the <strong>first 3\u2011year sustained\u2011release corticosteroid implant<\/strong> toward China market entry.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-clinical-milestone\">Regulatory &amp; Clinical Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Ocumension Therapeutics (1477.HK)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>OT-703 (fluocinonide intravitreal implant)<\/td><\/tr><tr><td><strong>Study<\/strong><\/td><td>Real\u2011world study in Bo\u2019ao Lecheng Pilot Zone<\/td><\/tr><tr><td>**Enrollment<\/td><td>195 patients<\/td><\/tr><tr><td>**Indication<\/td><td>Diabetic macular edema (DME)<\/td><\/tr><tr><td>**Technology<\/td><td>Sustained\u2011release corticosteroid implant (up to 3 years)<\/td><\/tr><tr><td><strong>Licensing<\/strong><\/td><td>Rights from Alimera Sciences (April 2021)<\/td><\/tr><tr><td>**Territory<\/td><td>Greater China, South Korea, Southeast Asia<\/td><\/tr><tr><td>**US Status<\/td><td>Approved as Iluvien (only 3\u2011year DME implant)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>Fluocinonide<\/strong> (potent corticosteroid) delivered via <strong>non\u2011bioerodible intravitreal implant<\/strong><\/li>\n\n\n\n<li><strong>Duration:<\/strong> Provides <strong>continuous drug release for up to 36 months<\/strong>, reducing treatment burden vs. monthly anti\u2011VEGF injections<\/li>\n\n\n\n<li><strong>Efficacy:<\/strong> <strong>Iluvien<\/strong> (US approved) demonstrated <strong>visual acuity improvement<\/strong> in 30\u201140% of DME patients and <strong>reduced injection frequency by 70%<\/strong><\/li>\n\n\n\n<li><strong>Bo\u2019ao Advantage:<\/strong> Pilot zone approval allows <strong>treatment of paying patients<\/strong> while generating real\u2011world evidence for NMPA review<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China<\/th><th>Global<\/th><\/tr><\/thead><tbody><tr><td><strong>DME Patients (2026E)<\/strong><\/td><td>5.2\u202fmillion<\/td><td>21.0\u202fmillion<\/td><\/tr><tr><td><strong>Anti\u2011VEGF\u2011Eligible<\/strong><\/td><td>2.8\u202fmillion<\/td><td>11.5\u202fmillion<\/td><\/tr><tr><td><strong>Sustained\u2011Release Implant Penetration<\/strong><\/td><td>&lt;2\u202f%<\/td><td>12\u202f%<\/td><\/tr><tr><td><strong>Market Value (2030E)<\/strong><\/td><td>\u00a545\u202fbillion<\/td><td>$12.5\u202fbillion<\/td><\/tr><tr><td><strong>Iluvien US Sales (2025)<\/strong><\/td><td>\u2013<\/td><td>$285\u202fmillion<\/td><\/tr><tr><td><strong>OT-703 Peak Share<\/strong><\/td><td>8\u202f%<\/td><td>2\u202f%<\/td><\/tr><tr><td><strong>Peak Revenue (2032E)<\/strong><\/td><td>\u00a53.6\u202fbillion<\/td><td>$250\u202fmillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Anti\u2011VEGF Injections:<\/strong> Eylea, Lucentis, Beovu \u2013 dominate China market but require monthly dosing<\/li>\n\n\n\n<li><strong>Ozurdex<\/strong> (Allergan) \u2013 6\u2011month dexamethasone implant, limited DME efficacy<\/li>\n\n\n\n<li><strong>Yutiq<\/strong> (EyePoint) \u2013 non\u2011DME indication, shorter duration<\/li>\n\n\n\n<li><strong>OT-703<\/strong> \u2013 <strong>First 3\u2011year implant<\/strong> in China; <strong>differentiated convenience<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing:<\/strong> Ocumension\u2019s <strong>Suzhou facility<\/strong> (capacity 500,000 implants\/year) will produce OT-703 for China; <strong>GMP certification<\/strong> achieved in 2025<\/li>\n\n\n\n<li><strong>Clinical Development:<\/strong> <strong>Real\u2011world study<\/strong> data will support <strong>NDA submission<\/strong> to NMPA by <strong>Q4\u202f2026<\/strong>; <strong>Phase\u202fIII bridging trial<\/strong> vs. Iluvien planned for 2027<\/li>\n\n\n\n<li><strong>Commercial Reach:<\/strong> <strong>800\u2011person ophthalmology sales force<\/strong> established for existing products; OT-703 launch targeted for <strong>Q3\u202f2027<\/strong><\/li>\n\n\n\n<li><strong>Reimbursement Strategy:<\/strong> Positioning as <strong>premium DME therapy<\/strong> (\u00a515,000\u201118,000 per implant) with <strong>NRDL Category\u202f1 negotiation<\/strong> planned for 2028<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory approvals, and commercial forecasts for OT-703. Actual results may differ due to competitive responses, pricing negotiations, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026012000038_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026012000038_c.\"><\/object><a id=\"wp-block-file--media-0beb289c-e85d-4031-a0ee-cf14fc7b6247\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026012000038_c.pdf\">2026012000038_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026012000038_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-0beb289c-e85d-4031-a0ee-cf14fc7b6247\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ocumension Therapeutics (HKG: 1477) announced completion of enrollment for a real\u2011world study of OT-703 (fluocinonide&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[936,156,44],"class_list":["post-54897","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-hkg-1477","tag-ocumension-therapeutics","tag-ophthalmology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ocumension\u2019s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ocumension Therapeutics (HKG: 1477) announced completion of enrollment for a real\u2011world study of OT-703 (fluocinonide intravitreal implant) in Bo\u2019ao Lecheng International Medical Tourism Pilot Zone, enrolling 195 patients with diabetic macular edema (DME) as the company advances the first 3\u2011year sustained\u2011release corticosteroid implant toward China market entry.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54897\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocumension\u2019s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study\" \/>\n<meta property=\"og:description\" content=\"Ocumension Therapeutics (HKG: 1477) announced completion of enrollment for a real\u2011world study of OT-703 (fluocinonide intravitreal implant) in Bo\u2019ao Lecheng International Medical Tourism Pilot Zone, enrolling 195 patients with diabetic macular edema (DME) as the company advances the first 3\u2011year sustained\u2011release corticosteroid implant toward China market entry.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54897\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-20T12:46:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-20T12:46:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54897#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54897\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ocumension\u2019s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study\",\"datePublished\":\"2026-01-20T12:46:26+00:00\",\"dateModified\":\"2026-01-20T12:46:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54897\"},\"wordCount\":379,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 1477\",\"Ocumension Therapeutics\",\"Ophthalmology\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54897#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54897\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54897\",\"name\":\"Ocumension\u2019s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-20T12:46:26+00:00\",\"dateModified\":\"2026-01-20T12:46:28+00:00\",\"description\":\"Ocumension Therapeutics (HKG: 1477) announced completion of enrollment for a real\u2011world study of OT-703 (fluocinonide intravitreal implant) in Bo\u2019ao Lecheng International Medical Tourism Pilot Zone, enrolling 195 patients with diabetic macular edema (DME) as the company advances the first 3\u2011year sustained\u2011release corticosteroid implant toward China market entry.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54897#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54897\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54897#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ocumension\u2019s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ocumension\u2019s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study - Insight, China&#039;s Pharmaceutical Industry","description":"Ocumension Therapeutics (HKG: 1477) announced completion of enrollment for a real\u2011world study of OT-703 (fluocinonide intravitreal implant) in Bo\u2019ao Lecheng International Medical Tourism Pilot Zone, enrolling 195 patients with diabetic macular edema (DME) as the company advances the first 3\u2011year sustained\u2011release corticosteroid implant toward China market entry.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54897","og_locale":"en_US","og_type":"article","og_title":"Ocumension\u2019s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study","og_description":"Ocumension Therapeutics (HKG: 1477) announced completion of enrollment for a real\u2011world study of OT-703 (fluocinonide intravitreal implant) in Bo\u2019ao Lecheng International Medical Tourism Pilot Zone, enrolling 195 patients with diabetic macular edema (DME) as the company advances the first 3\u2011year sustained\u2011release corticosteroid implant toward China market entry.","og_url":"https:\/\/flcube.com\/?p=54897","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-20T12:46:26+00:00","article_modified_time":"2026-01-20T12:46:28+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54897#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54897"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ocumension\u2019s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study","datePublished":"2026-01-20T12:46:26+00:00","dateModified":"2026-01-20T12:46:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54897"},"wordCount":379,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 1477","Ocumension Therapeutics","Ophthalmology"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54897#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54897","url":"https:\/\/flcube.com\/?p=54897","name":"Ocumension\u2019s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-20T12:46:26+00:00","dateModified":"2026-01-20T12:46:28+00:00","description":"Ocumension Therapeutics (HKG: 1477) announced completion of enrollment for a real\u2011world study of OT-703 (fluocinonide intravitreal implant) in Bo\u2019ao Lecheng International Medical Tourism Pilot Zone, enrolling 195 patients with diabetic macular edema (DME) as the company advances the first 3\u2011year sustained\u2011release corticosteroid implant toward China market entry.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54897#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54897"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54897#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ocumension\u2019s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54897","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54897"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54897\/revisions"}],"predecessor-version":[{"id":54900,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54897\/revisions\/54900"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54897"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54897"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54897"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}